BR112022012273A2 - Composto, pirrolo[3,2-c]piridina, pirrolo[3,2-c]piridazina, indol, método para suprimir a expressão de oncogene em uma célula e método para tratar um paciente com leucemia - Google Patents
Composto, pirrolo[3,2-c]piridina, pirrolo[3,2-c]piridazina, indol, método para suprimir a expressão de oncogene em uma célula e método para tratar um paciente com leucemiaInfo
- Publication number
- BR112022012273A2 BR112022012273A2 BR112022012273A BR112022012273A BR112022012273A2 BR 112022012273 A2 BR112022012273 A2 BR 112022012273A2 BR 112022012273 A BR112022012273 A BR 112022012273A BR 112022012273 A BR112022012273 A BR 112022012273A BR 112022012273 A2 BR112022012273 A2 BR 112022012273A2
- Authority
- BR
- Brazil
- Prior art keywords
- leukemia
- pyrrollo
- pyrolo
- pyridazine
- indole
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962949160P | 2019-12-17 | 2019-12-17 | |
| PCT/US2020/065593 WO2021127166A1 (en) | 2019-12-17 | 2020-12-17 | Inhibitors of enl/af9 yeats |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022012273A2 true BR112022012273A2 (pt) | 2022-08-30 |
Family
ID=76476792
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022012273A BR112022012273A2 (pt) | 2019-12-17 | 2020-12-17 | Composto, pirrolo[3,2-c]piridina, pirrolo[3,2-c]piridazina, indol, método para suprimir a expressão de oncogene em uma célula e método para tratar um paciente com leucemia |
Country Status (14)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024518824A (ja) | 2021-05-13 | 2024-05-07 | ブリッジ メディシンズ | Ｅｎｌ／ａｆ９ ｙｅａｔｓのｃ結合阻害剤 |
| CN117580944A (zh) * | 2021-08-03 | 2024-02-20 | 苏州沙砾生物科技有限公司 | 一种修饰的免疫细胞及其用途 |
| US20250376473A1 (en) * | 2022-07-01 | 2025-12-11 | Cytosinlab Therapeutics Co., Ltd. | Prmts inhibitor and use thereof |
| GB202213164D0 (en) | 2022-09-08 | 2022-10-26 | Cambridge Entpr Ltd | Novel compounds, compositions and therapeutic uses thereof |
| GB202213163D0 (en) | 2022-09-08 | 2022-10-26 | Cambridge Entpr Ltd | Novel compounds, compositions and therapeutic uses thereof |
| US20260078121A1 (en) * | 2022-09-08 | 2026-03-19 | Bridge Medicines | Inhibitors of enl/af9 yeats and flt3 |
| WO2024140923A1 (zh) * | 2022-12-30 | 2024-07-04 | 苏州浦合医药科技有限公司 | Prmt5-mta抑制剂 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2375359C2 (ru) * | 2004-09-03 | 2009-12-10 | Юхан Корпорейшн | ПРОИЗВОДНЫЕ ПИРРОЛО[3, 2-c]ПИРИДИНА И СПОСОБЫ ИХ ПОЛУЧЕНИЯ |
| US20110015225A1 (en) * | 2008-04-01 | 2011-01-20 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| EP2522657B1 (en) * | 2010-01-06 | 2016-08-03 | Takeda Pharmaceutical Company Limited | Indole derivative |
| EP2818472A1 (en) * | 2013-06-27 | 2014-12-31 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Imidazo[4,5-c]pyridine and pyrrolo[3,2-c]pyridine compounds as G-protein-coupled receptor kinase 5 (GRK5) modulators |
| WO2022146920A1 (en) * | 2020-12-28 | 2022-07-07 | Celgene Corporation | Heterocyclic compounds and their use for parasitic diseases |
| JP2024518824A (ja) * | 2021-05-13 | 2024-05-07 | ブリッジ メディシンズ | Ｅｎｌ／ａｆ９ ｙｅａｔｓのｃ結合阻害剤 |
-
2020
- 2020-12-17 CR CR20220326A patent/CR20220326A/es unknown
- 2020-12-17 AU AU2020407589A patent/AU2020407589A1/en active Pending
- 2020-12-17 JP JP2022538193A patent/JP7840851B2/ja active Active
- 2020-12-17 WO PCT/US2020/065593 patent/WO2021127166A1/en not_active Ceased
- 2020-12-17 US US17/757,492 patent/US20230027198A1/en active Pending
- 2020-12-17 EP EP20903540.1A patent/EP4076440B1/en active Active
- 2020-12-17 CA CA3162253A patent/CA3162253A1/en active Pending
- 2020-12-17 IL IL293839A patent/IL293839A/en unknown
- 2020-12-17 BR BR112022012273A patent/BR112022012273A2/pt unknown
- 2020-12-17 KR KR1020227024539A patent/KR20220129554A/ko active Pending
- 2020-12-17 CN CN202510375451.1A patent/CN120289456A/zh active Pending
- 2020-12-17 PH PH1/2022/551529A patent/PH12022551529A1/en unknown
- 2020-12-17 MX MX2022007442A patent/MX2022007442A/es unknown
- 2020-12-17 CN CN202080096854.8A patent/CN115427035B/zh active Active
-
2022
- 2022-07-13 CO CONC2022/0009852A patent/CO2022009852A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023527487A (ja) | 2023-06-29 |
| CA3162253A1 (en) | 2021-06-24 |
| JP7840851B2 (ja) | 2026-04-06 |
| CN115427035B (zh) | 2025-04-22 |
| CO2022009852A2 (es) | 2022-10-11 |
| MX2022007442A (es) | 2023-02-13 |
| EP4076440A1 (en) | 2022-10-26 |
| US20230027198A1 (en) | 2023-01-26 |
| EP4076440B1 (en) | 2026-07-08 |
| IL293839A (en) | 2022-08-01 |
| KR20220129554A (ko) | 2022-09-23 |
| CR20220326A (es) | 2023-02-10 |
| PH12022551529A1 (en) | 2024-02-05 |
| CN115427035A (zh) | 2022-12-02 |
| WO2021127166A1 (en) | 2021-06-24 |
| AU2020407589A1 (en) | 2022-07-21 |
| EP4076440A4 (en) | 2023-11-08 |
| CN120289456A (zh) | 2025-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020551332A1 (en) | Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors | |
| MX2023010429A (es) | Inhibidores del homologo del oncogen viral del sarcoma de rata kirsten (kras). | |
| MX2024014142A (es) | Novedosos inhibidores de molecula peque?a de factores de transcripcion tead | |
| NZ758345A (en) | Ask1 inhibitor compounds and uses thereof | |
| PH12022550470A1 (en) | Triazolopyrimidines as a2a / a2b inhibitors | |
| MX2023011883A (es) | Terapias combinadas con compuestos inhibidores de cbl-b. | |
| MX2020008244A (es) | Composiciones y metodos para el tratamiento del cancer y de trastornos inmunitarios usando bacterias de veillonella. | |
| NZ744349A (en) | Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors | |
| EA201992322A3 (ru) | Соединения и композиции для лечения гематологических расстройств | |
| MX2009013341A (es) | Derivados de 6-(pirrolopiridinil)-pirimidinil-2-amina. | |
| PH12022551529A1 (en) | Inhibitors of enl/af9 yeats | |
| ZA202105353B (en) | Pyrazolopyridines and triazolopyridines as a2a / a2b inhibitors | |
| MX2022000310A (es) | Inhibidores de proteina bcl-2. | |
| TW200614990A (en) | Methods for preparing indazole compounds | |
| DOP2023000129A (es) | DERIVADOS DE INDOL ÚTILES EN EL TRATAMIENTO DE AFECCIONES ASOCIADAS CON cGAS | |
| MX2009000420A (es) | Derivados de isoindolina para el tratamiento de arritmias. | |
| MX2021002051A (es) | Imidazo[1,2-b]piridaziinas como inhibidores de trk. | |
| IL205696A0 (en) | Heterocyclic derivatives, compositions comprising the same and uses thereof | |
| MX2021011524A (es) | Inhibidores de proteina arginina n-metiltransferasa 5 (prmt5) y usos de los mismos. | |
| PH12020551343A1 (en) | 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer | |
| MX2022002069A (es) | Inhibidores de enzimas. | |
| CO6382175A2 (es) | Metodo para inhibir la cinasa del c-kit | |
| NZ779815A (en) | Indazolyl-isoxazole derivatives for the treatment of diseases such as cancer | |
| NO20070589L (no) | Mitotiske kinesin-inhibitorer. | |
| WO2019075216A8 (en) | Plectin-1 binding antibodies and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25G | Requested change of headquarter approved |
Owner name: THE ROCKEFELLER UNIVERSITY (US) ; BRIDGE MEDICINES, LLC (US) ; TANWEER A. KHAN (US) ; NIGEL LIVERTON (US) ; YOSHIYUKI FUKASE (US) ; MAYAKO MICHINO (US) ; ANDREW W. STAMFORD (US) ; MICHAEL W. MILLER (US) ; DAVID HUGGINS (US) ; PETER MEINKE (US) |
|
| B25G | Requested change of headquarter approved |
Owner name: THE ROCKEFELLER UNIVERSITY (US) ; BRIDGE MEDICINES, LLC (US) ; TANWEER A. KHAN (US) ; NIGEL LIVERTON (US) ; YOSHIYUKI FUKASE (US) ; MAYAKO MICHINO (US) ; ANDREW W. STAMFORD (US) ; MICHAEL W. MILLER (US) ; DAVID HUGGINS (US) ; PETER MEINKE (US) |
|
| B25A | Requested transfer of rights approved |
Owner name: THE ROCKEFELLER UNIVERSITY (US) ; BRIDGE MEDICINES, LLC (US) ; TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, INC. (US) |
|
| B25A | Requested transfer of rights approved |
Owner name: THE ROCKEFELLER UNIVERSITY (US) ; BRIDGE MEDICINES, LLC (US) |
|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |